AbbVie’s migraine treatment meets late-stage study goal
Sept 10 (Reuters) – AbbVie said on Thursday its migraine treatment had met the main goal of a late-stage study testing it as a preventive treatment of menstrual migraine in adults. (Reporting by Sneha S K in Bengaluru; Editing by Shreya Biswas) Brought to you by www.srnnews.com